RxDoctor Payments Data

Amir Lotfi, MD

Interventional Cardiology · Springfield, MANPI 1790714400

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (36.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 53.2% of the total. 2025 is the largest year on record at $8,637, more than ten times the $303 reported in 2019.

$19,744in general payments, 2019–2025

Across 122 payments — averaging $161.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$3K
  • Abbott$3K
  • Philips North America LLC$2K
  • Edwards Lifesciences$599
  • Biosense Webster, Inc.$148
  • plus $363 from 6 others
$830,215in research payments, 2019–2025

Across 149 payments — averaging $5571.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Circulation Inc$664K
  • Boston Scientific$100K
  • Shockwave Medical, Inc$54K
  • Biotronik Inc.$12K

What the payments were for

  • Consulting fees$5,77529%
  • Travel & lodging$6,83335%
  • Food & beverage$7,13636%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,744 in reported general payments places this provider in the 70th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$128,914
Medicare patients
685
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$109,794
XareltoRivaroxaban32$25,642
EntrestoSacubitril/Valsartan14$13,303
Repatha SureclickEvolocumab19$10,470
JardianceEmpagliflozin14$9,424
BrilintaTicagrelor11$5,727
Metoprolol Succinate205$4,074
Atorvastatin Calcium237$3,272
Rosuvastatin Calcium39$1,982
ClopidogrelClopidogrel Bisulfate134$1,942
Ezetimibe28$1,183
Isosorbide Mononitrate ErIsosorbide Mononitrate73$1,081
Valsartan18$889
Carvedilol58$846
Amlodipine Besylate105$755

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →